Autolus Therapeutics plc
AUTL· Nasdaq
AUTLAutolus Therapeutics plc
Source filing unavailable
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018 |
|---|---|---|---|---|
| Revenue | — | — | $309.00K | $296.00K |
| Net Income | -$26.95M | -$42.86M | -$40.94M | -$20.65M |
| EPS Diluted | — | — |
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
| — |
| -$0.52 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
